A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in Type 2 diabetes mellitus
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Skeletal muscle mitochondrial dysfunction is hypothesized to contribute to the pathophysiology of insulin resistance and Type 2 diabetes. Whether thiazolidinedione therapy enhances skeletal muscle mitochondrial function as a component of its insulin-sensitizing effect is unknown. To test this, we evaluated skeletal muscle mitochondria and exercise capacity in Type 2 diabetic subjects with otherwise normal cardiopulmonary function in response to rosiglitazone therapy. Twenty-three subjects were treated for 12 wk and underwent pre- and posttherapy metabolic stress testing and skeletal muscle biopsies. Rosiglitazone significantly ameliorated fasting glucose, insulin, and free fatty acid levels but did not augment the subjects' maximal oxygen consumption (V̇o 2max) or their skeletal muscle mitochondrial copy number. The baseline V̇o 2max correlated strongly with muscle mitochondrial copy number ( r = 0.56, P = 0.018, n = 17) and inversely with the duration of diabetes ( r = −0.67, P = 0.004, n = 23). Despite the global lack of effect of rosiglitazone-mediated insulin sensitization on skeletal muscle mitochondria, subjects with the most preserved functional capacity demonstrated some plasticity in their mitochondria biology as evidenced by an upregulation of electron transfer chain proteins and in citrate synthase activity. This study demonstrates that the augmentation of skeletal muscle mitochondrial electron transfer chain content and/or bioenergetics is not a prerequisite for rosiglitazone-mediated improved insulin sensitivity. Moreover, in diabetic subjects, V̇o 2max reflects the duration of diabetes and skeletal muscle mitochondrial content. It remains to be determined whether longer-term insulin sensitization therapy with rosiglitazone will augment skeletal muscle mitochondrial bioenergetics in those diabetic subjects with relatively preserved basal aerobic capacity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2006) · The Lancet · doi:10.1016/s0140-6736(06)69420-8 · Cited by 1,706 · cited 2×
“In light of the accumulating evidence supporting interventions to delay the progression of diabetes (7, 13), the finding of a relatively maintained V̇O2max may have added motivational benefit for these individuals identified as being in the early stages of this disease.”
Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Martin, B. C., Warram, J. H., Krolewski, A. S., Soeldner, J. S., Kahn, C. R., Martin, B. C., & Bergman, R. N. (1992) · The Lancet · doi:10.1016/0140-6736(92)92814-v · Cited by 1,158 · cited 2×
“Insulin resistance is the best predictor of the future development of type 2 diabetes (19).”
Morino, K. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25151 · Cited by 811 · cited 2×
“Skeletal muscle of insulin-resistant subjects has diminished mitochondrial density (24) and reduced mitochondrial oxidative phosphorylation (27).”
Lillioja, S., Young, A. A., Culter, C. L., Ivy, J. L., Abbott, W. G., Zawadzki, J. K., Yki-Järvinen, H., Christin, L., Secomb, T. W., & Bogardus, C. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113088 · Cited by 782
Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone.
Wilson-Fritch, L., Nicoloro, S., Chouinard, M., Lazar, M. A., Chui, P. C., Leszyk, J., Straubhaar, J., Czech, M. P., & Corvera, S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21752 · Cited by 616 · cited 2×
“The PPAR agonist rosiglitazone has been shown to improve mitochondrial respiration in adipocytes of ob/ob mice (39) and to upregulate the adipocyte mitochondrial biogenesis regulatory program in two mouse models of obesity/diabetes (31).”
Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes
Mogensen, M., Sahlin, K., Fernström, M., Glintborg, D., Vind, B. F., Beck-Nielsen, H., & Højlund, K. (2007) · Diabetes · doi:10.2337/db06-0981 · Cited by 573 · cited 1×
“Diabetic individuals also show coordinate downregulation of genes encoding the oxidative phosphorylation enzymes (22) and diminished skeletal muscle mitochondrial respiration (23), and evidence of reduced skeletal muscle bioenergetic capacity as illustrated by slower recovery of skeletal muscle high-energy phosphate s…”
Abnormal Cardiac and Skeletal Muscle Energy Metabolism in Patients With Type 2 Diabetes
Scheuermann-Freestone, M., Madsen, P. L., Manners, D., Blamire, A. M., Buckingham, R. E., Styles, P., Radda, G. K., Neubauer, S., & Clarke, K. (2003) · Circulation · doi:10.1161/01.cir.0000072789.89096.10 · Cited by 525
Wei, M., Gibbons, L. W., Mitchell, T. L., Kampert, J. B., Lee, C. D., & Blair, S. N. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-2-199901190-00002 · Cited by 472
Pioglitazone Induces Mitochondrial Biogenesis in Human Subcutaneous Adipose Tissue In Vivo
Bogacka, I., Xie, H., Bray, G. A., & Smith, S. R. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1392 · Cited by 467
Tarnopolsky, M. A., Rennie, C. D., Robertshaw, H. A., Fedak-Tarnopolsky, S. N., Devries, M. C., & Hamadeh, M. J. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00472.2006 · Cited by 457
Befroy, D. E., Petersen, K. F., Dufour, S., Mason, G. F., de Graaf, R. A., Rothman, D. L., & Shulman, G. I. (2007) · Diabetes · doi:10.2337/db06-0783 · Cited by 453 · cited 1×
“It has recently been demonstrated that skeletal muscle mitochondrial substrate oxidation is impaired in insulin-resistant offspring of Type 2 diabetic patients (2).”
Simoneau, J.-A., & Kelley, D. E. (1997) · Journal of Applied Physiology · doi:10.1152/jappl.1997.83.1.166 · Cited by 441
Rong, J. X., Qiu, Y., Hansen, M. K., Zhu, L., Zhang, V., Xie, M., Okamoto, Y., Mattie, M. D., Higashiyama, H., Asano, S., et al. (2007) · Diabetes · doi:10.2337/db06-1135 · Cited by 335 · cited 2×
“In fact, the difference in plasticity seen in our study compared with the robust induction of mitochondrial biogenesis in adipocytes in response to rosiglitazone (31) may reflect the relative lower abundance of PPAR in skeletal muscle compared with expression in adipose tissue (17, 35).”
Petersen, K. F., Dufour, S., & Shulman, G. I. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020233 · Cited by 308
Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis
Meyer, C., Dostou, J. M., Welle, S. L., & Gerich, J. E. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00032.2001 · Cited by 269 · cited 1×
“Because skeletal muscle is a predominant reservoir for postprandial glucose uptake (21) and skeletal muscle insulin resistance is proposed to be pivotal in the development of diabetes, the question arising is whether restoration of mitochondrial biology in skeletal muscle is central to the insulin-sensitizing effects…”
Heilbronn, L. K., Gan, S. K., Turner, N., Campbell, L. V., & Chisholm, D. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2210 · Cited by 184
Exercise capacity and body mass as predictors of mortality among male veterans with type 2 diabetes
McAuley, P. A., Myers, J. N., Abella, J. P., Tan, S. Y., & Froelicher, V. F. (2007) · Diabetes Care · doi:10.2337/dc06-2397 · Cited by 69
Cited by
The role of mitochondria in insulin resistance and type 2 diabetes mellitus
Szendroedi, J., Phielix, E., & Roden, M. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.138 · Cited by 600
Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus
Hesselink, M. K. C., Schrauwen-Hinderling, V., & Schrauwen, P. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.104 · Cited by 242
The Role of Mitochondria in the Pathophysiology of Skeletal Muscle Insulin Resistance
Pagel-Langenickel, I., Bao, J., Pang, L., & Sack, M. N. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0003 · Cited by 154
“jects with relatively preserved VO2max and mitochondrial copy numbers (61).”
Self-citationPagel-Langenickel, I., Bao, J., Joseph, J. J., Schwartz, D. R., Mantell, B. S., Xu, X., Raghavachari, N., & Sack, M. N. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800842200 · Cited by 124
Self-citationTaub, P. R., Ramirez‐Sanchez, I., Ciaraldi, T. P., Perkins, G., Murphy, A. N., Naviaux, R., Hogan, M., Maisel, A. S., Henry, R. R., Ceballos, G., et al. (2012) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2011.00357.x · Cited by 122
Metadata
- Authors
- Pagel-Langenickel, I., Schwartz, D. R., Arena, R. A., Minerbi, D. C., Johnson, D. T., Waclawiw, M. A., Cannon, R. O., Balaban, R. S., Tripodi, D. J., & Sack, M. N.
- Venue
- American Journal of Physiology-Heart and Circulatory Physiology
- Publisher
- American Physiological Society
- Published
- 2007-11
- Volume
- 293
- Issue
- 5
- Pages
- H2659-H2666
- ISSN
- 0363-6135 (ISSN-L)
- 1522-1539
- OpenAlex
- W2103674129
- Cited by
- 21
- References
- 19
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.